Postlicensure epidemiology of childhood vaccination: the Danish experience

被引:30
作者
Hviid, Anders [1 ]
机构
[1] Statens Serum Inst, Dept Epidemiol Res, DK-2300 Copenhagen S, Denmark
关键词
epidemiology; immunization; postlicensure; vaccines;
D O I
10.1586/14760584.5.5.641
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The efficacy, the ability to confer protection against a target disease and the safety of a vaccine are assessed in great detail before licensure. However, inherent limitations in the prelicensure assessment necessitate continued epidemiological evaluations of efficacy and safety issues after the introduction of vaccines into use. In Denmark, the opportunities available for epidemiological research are unique. In 2001, an initiative was undertaken to take advantage of these opportunities to study the postlicensure epidemiology of childhood vaccination with respect to effectiveness and safety. First, we describe the unique opportunities for postlicensure research in Denmark with respect to the data sources available and the epidemiological and statistical methods used. We then describe a number of recent postlicensure studies of effectiveness and safety that took advantage of these opportunities. Specifically, studies on the effectiveness of Hoemophilus influenzoe type b vaccination, the effectiveness of pertussis vaccination, the impact of a preschool pertussis booster on infant pertussis, measles-mumps-rubella vaccine and autism, thimerosal-containing vaccine and autism, measles-mumps-rubella vaccine and febrile seizures, childhood vaccination and Type I diabetes, and childhood vaccination and nontargeted infectious disease are discussed.
引用
收藏
页码:641 / 649
页数:9
相关论文
共 51 条
  • [31] A population-based study of measles, mumps, and rubella vaccination and autism
    Madsen, KM
    Hviid, A
    Vestergaard, M
    Schendel, D
    Wohlfahrt, J
    Thorsen, P
    Olsen, J
    Melbye, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (19) : 1477 - 1482
  • [32] Neurologic disorders after measles-mumps-rubella vaccination
    Mäkelä, A
    Nuorti, JP
    Peltola, H
    [J]. PEDIATRICS, 2002, 110 (05) : 957 - 963
  • [33] MALIG C, 1996, 66 IIVRS
  • [34] EIGHTH REVISION OF INTERNATIONAL CLASSIFICATION OF DISEASES
    MORIYAMA, IM
    [J]. AMERICAN JOURNAL OF PUBLIC HEALTH AND THE NATIONS HEALTH, 1966, 56 (08): : 1277 - &
  • [35] MunkJorgensen P, 1997, DAN MED BULL, V44, P82
  • [36] Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children (Retraction of vol 351, pg 637, 1998)
    Murch, SH
    Anthony, A
    Casson, DH
    Malik, M
    Berelowitz, M
    Dhillon, AP
    Thomson, MA
    Valentine, A
    Davies, SE
    Walker-Smith, JA
    [J]. LANCET, 2004, 363 (9411) : 750 - 750
  • [37] Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century:: Global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates
    Peltola, H
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 2000, 13 (02) : 302 - +
  • [38] No evidence for measles, mumps, and rubella vaccine-associated inflammatory bowel disease or autism in a 14-year prospective study
    Peltola, H
    Patja, A
    Leinikki, P
    Valle, M
    Davidkin, I
    Paunio, M
    [J]. LANCET, 1998, 351 (9112) : 1327 - 1328
  • [39] MMR vaccination and pervasive developmental disorders: a case-control study
    Smeeth, L
    Cook, C
    Fombonne, E
    Heavey, L
    Rodrigues, LC
    Smith, PG
    Hall, AJ
    [J]. LANCET, 2004, 364 (9438) : 963 - 969
  • [40] Stratton K., 2004, Immunization safety review